Jared Barsky
Examiner (ID: 13656, Phone: (571)272-2795 , Office: P/1628 )
Most Active Art Unit | 1628 |
Art Unit(s) | 1628 |
Total Applications | 964 |
Issued Applications | 443 |
Pending Applications | 93 |
Abandoned Applications | 428 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16051227
[patent_doc_number] => 20200187468
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => NON-HUMAN ANIMALS HAVING A HUMANIZED SIGNAL-REGULATORY PROTEIN GENE
[patent_app_type] => utility
[patent_app_number] => 16/541334
[patent_app_country] => US
[patent_app_date] => 2019-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16878
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16541334
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/541334 | Non-human animals having a humanized signal-regulatory protein gene | Aug 14, 2019 | Issued |
Array
(
[id] => 15408093
[patent_doc_number] => 20200024368
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-23
[patent_title] => MICE EXPRESSING A LIMITED IMMUNOGLOBULIN LIGHT CHAIN REPERTOIRE
[patent_app_type] => utility
[patent_app_number] => 16/530030
[patent_app_country] => US
[patent_app_date] => 2019-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46671
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530030
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/530030 | Mice expressing a limited immunoglobulin light chain repertoire | Aug 1, 2019 | Issued |
Array
(
[id] => 16412724
[patent_doc_number] => 10820580
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-03
[patent_title] => Immunodeficient non-human animal
[patent_app_type] => utility
[patent_app_number] => 16/435080
[patent_app_country] => US
[patent_app_date] => 2019-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 29
[patent_no_of_words] => 17123
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16435080
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/435080 | Immunodeficient non-human animal | Jun 6, 2019 | Issued |
Array
(
[id] => 17618386
[patent_doc_number] => 11337409
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-24
[patent_title] => Transgenic animal for producing diversified antibodies that have the same light chain I
[patent_app_type] => utility
[patent_app_number] => 15/734187
[patent_app_country] => US
[patent_app_date] => 2019-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 20
[patent_no_of_words] => 14576
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 141
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734187
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/734187 | Transgenic animal for producing diversified antibodies that have the same light chain I | Jun 4, 2019 | Issued |
Array
(
[id] => 19472011
[patent_doc_number] => 12102070
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-01
[patent_title] => Camelization of a human variable domain by gene conversion
[patent_app_type] => utility
[patent_app_number] => 15/734534
[patent_app_country] => US
[patent_app_date] => 2019-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 4
[patent_no_of_words] => 8983
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 194
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734534
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/734534 | CAMELIZATION OF A HUMAN VARIABLE DOMAIN BY GENE CONVERSION | Jun 4, 2019 | Pending |
Array
(
[id] => 16870516
[patent_doc_number] => 20210163983
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => TRANSGENIC ANIMAL FOR PRODUCING DIVERSIFIED ANTIBODIES THAT HAVE THE SAME LIGHT CHAIN II
[patent_app_type] => utility
[patent_app_number] => 15/734189
[patent_app_country] => US
[patent_app_date] => 2019-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14568
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734189
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/734189 | TRANSGENIC ANIMAL FOR PRODUCING DIVERSIFIED ANTIBODIES THAT HAVE THE SAME LIGHT CHAIN II | Jun 4, 2019 | Pending |
Array
(
[id] => 16989390
[patent_doc_number] => 20210227810
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => PRODUCTION OF ANTIBODIES BY MODIFICATION OF AN AUTONOMOUS HEAVY CHAIN VARIABLE DOMAIN BY GENE CONVERSION
[patent_app_type] => utility
[patent_app_number] => 15/734533
[patent_app_country] => US
[patent_app_date] => 2019-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8997
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734533
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/734533 | PRODUCTION OF ANTIBODIES BY MODIFICATION OF AN AUTONOMOUS HEAVY CHAIN VARIABLE DOMAIN BY GENE CONVERSION | Jun 4, 2019 | Pending |
Array
(
[id] => 17451852
[patent_doc_number] => 11266689
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-08
[patent_title] => NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
[patent_app_type] => utility
[patent_app_number] => 16/429581
[patent_app_country] => US
[patent_app_date] => 2019-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 40
[patent_no_of_words] => 17104
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16429581
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/429581 | NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same | Jun 2, 2019 | Issued |
Array
(
[id] => 16648112
[patent_doc_number] => 10925264
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-23
[patent_title] => Genetically modified non-human animal with human or chimeric LAG-3
[patent_app_type] => utility
[patent_app_number] => 16/409683
[patent_app_country] => US
[patent_app_date] => 2019-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 24
[patent_no_of_words] => 22577
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409683
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/409683 | Genetically modified non-human animal with human or chimeric LAG-3 | May 9, 2019 | Issued |
Array
(
[id] => 16806174
[patent_doc_number] => 20210128727
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => A pharmaceutical combination for use in the treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 17/052835
[patent_app_country] => US
[patent_app_date] => 2019-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8208
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052835
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/052835 | A pharmaceutical combination for use in the treatment of cancer | May 6, 2019 | Pending |
Array
(
[id] => 16276828
[patent_doc_number] => 10759842
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-01
[patent_title] => T cell receptors and immune therapy using the same against prame positive cancers
[patent_app_type] => utility
[patent_app_number] => 16/403038
[patent_app_country] => US
[patent_app_date] => 2019-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 21460
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 252
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16403038
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/403038 | T cell receptors and immune therapy using the same against prame positive cancers | May 2, 2019 | Issued |
Array
(
[id] => 16276828
[patent_doc_number] => 10759842
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-01
[patent_title] => T cell receptors and immune therapy using the same against prame positive cancers
[patent_app_type] => utility
[patent_app_number] => 16/403038
[patent_app_country] => US
[patent_app_date] => 2019-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 21460
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 252
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16403038
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/403038 | T cell receptors and immune therapy using the same against prame positive cancers | May 2, 2019 | Issued |
Array
(
[id] => 16276828
[patent_doc_number] => 10759842
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-01
[patent_title] => T cell receptors and immune therapy using the same against prame positive cancers
[patent_app_type] => utility
[patent_app_number] => 16/403038
[patent_app_country] => US
[patent_app_date] => 2019-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 21460
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 252
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16403038
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/403038 | T cell receptors and immune therapy using the same against prame positive cancers | May 2, 2019 | Issued |
Array
(
[id] => 16276828
[patent_doc_number] => 10759842
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-01
[patent_title] => T cell receptors and immune therapy using the same against prame positive cancers
[patent_app_type] => utility
[patent_app_number] => 16/403038
[patent_app_country] => US
[patent_app_date] => 2019-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 21460
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 252
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16403038
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/403038 | T cell receptors and immune therapy using the same against prame positive cancers | May 2, 2019 | Issued |
Array
(
[id] => 15112921
[patent_doc_number] => 20190343093
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-14
[patent_title] => HUMANIZED IL-7 RODENTS
[patent_app_type] => utility
[patent_app_number] => 16/400074
[patent_app_country] => US
[patent_app_date] => 2019-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7980
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16400074
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/400074 | HUMANIZED IL-7 RODENTS | Apr 30, 2019 | Abandoned |
Array
(
[id] => 15994107
[patent_doc_number] => 20200172924
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => EXPERIMENTAL RESEARCH METHOD FOR TARGETED THERAPY OF PROSTATE CANCER BY NUCLIDE 125I-LABELED DUAL-REGULATION ONCOLYTIC ADENOVIRUS
[patent_app_type] => utility
[patent_app_number] => 16/392607
[patent_app_country] => US
[patent_app_date] => 2019-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2768
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16392607
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/392607 | EXPERIMENTAL RESEARCH METHOD FOR TARGETED THERAPY OF PROSTATE CANCER BY NUCLIDE 125I-LABELED DUAL-REGULATION ONCOLYTIC ADENOVIRUS | Apr 22, 2019 | Abandoned |
Array
(
[id] => 15360877
[patent_doc_number] => 20200016203
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-16
[patent_title] => Cell
[patent_app_type] => utility
[patent_app_number] => 16/392250
[patent_app_country] => US
[patent_app_date] => 2019-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20434
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16392250
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/392250 | Cell | Apr 22, 2019 | Abandoned |
Array
(
[id] => 14993803
[patent_doc_number] => 20190315859
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-17
[patent_title] => ANTIBODY AGENTS SPECIFIC FOR HUMAN CD19 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/388508
[patent_app_country] => US
[patent_app_date] => 2019-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57494
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16388508
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/388508 | Antibody agents specific for human CD19 and uses thereof | Apr 17, 2019 | Issued |
Array
(
[id] => 14989315
[patent_doc_number] => 20190313615
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-17
[patent_title] => METHODS FOR PROTECTING PORCINE FETUSES FROM INFECTION WITH PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV)
[patent_app_type] => utility
[patent_app_number] => 16/386901
[patent_app_country] => US
[patent_app_date] => 2019-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42115
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16386901
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/386901 | Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV) | Apr 16, 2019 | Issued |
Array
(
[id] => 15086925
[patent_doc_number] => 20190338273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => METHOD TO OVERCOME DNA CHEMICAL MODIFICATIONS SENSITIVITY OF ENGINEERED TALE DNA BINDING DOMAINS
[patent_app_type] => utility
[patent_app_number] => 16/379073
[patent_app_country] => US
[patent_app_date] => 2019-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18544
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16379073
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/379073 | Method to overcome DNA chemical modifications sensitivity of engineered TALE DNA binding domains | Apr 8, 2019 | Issued |